Association between thrombus composition and first-pass recanalization after thrombectomy in acute ischemic stroke.

Background: Achieving first-pass recanalization (FPR) has become the primary procedural objective during thrombectomy in acute ischemic stroke patients as it correlates with the best clinical outcome. Understanding factors contributing to FPR failures is essential to enhance FPR success rates. As the central target of thrombectomy, the thrombus itself may be a significant factor influencing FPR.
Objectives: This study aimed to investigate the association between thrombus composition and FPR success rates.
Methods: In total, thrombi from 267 ischemic stroke patients were collected in the AZ Groeninge Hospital (Kortrijk, Belgium). Thrombus composition was determined via detailed histologic analysis of red blood cells (RBCs), fibrin, von Willebrand factor, platelets, leukocytes, citrullinated histone 3 (marker for neutrophil extracellular traps), and intracellular and extracellular DNA. FPR was defined as obtaining a modified thrombolysis in cerebral infarction (mTICI) score of 2c/3 after the first pass.
Results: An mTICI score of 2c/3 was obtained in 180 patients, which was achieved via a successful FPR procedure in 126 cases or after multiple passes in 54 cases. Interestingly, thrombi from FPR cases had a different composition from thrombi that needed multiple passes to obtain an mTICI score of 2c/3. FPR thrombi contained significantly more RBCs (P = .0264), less fibrin (P = .0196), and less extracellular DNA (P = .0457).
Conclusion: Our results indicate that thrombi characterized by lower RBC content, higher fibrin levels, and increased extracellular DNA are less likely to result in an FPR. These results are important to guide future research aiming at improving procedures or technologies to obtain FPR rates in RBC-poor thrombi.
Competing Interests: Declaration of competing interests P.V. received speaker fees from Boehringer-Ingelheim, BMS, Pfizer, Daiichi-Sankyo, and Medtronic. T.A. holds equity for Cereflo Ltd and is a consultant for Anaconda, Cerenovus/Neuravi, Optimize Neurovascular, and Rapid Medical. O.F. is a consultant for iVascular. All other authors have no conflicting interests.
(Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved.)